Inventiva H1 2026 Results and Comprehensive Refinancing Update

Inventiva S.A. reported its unaudited financial results for the first half of 2026 and provided a significant corporate update. The company is focused on its lead candidate, lanifibranor, currently in the pivotal Phase III NATiV3 clinical trial for MASH. Enrollment for the main cohort of NATiV3 was completed in April 2025, with topline results targeted for Q4 2026. A major highlight was the June 2026 comprehensive refinancing transaction, which included a $120 million equity offering, the repayment of a €50 million EIB loan, and a debt financing deal with BlackRock and Claret Capital. This transaction restructured the company's balance sheet, notably through the repurchase and cancellation of legacy EIB warrants and the issuance of new warrants. Inventiva also strengthened its leadership team with the appointments of a new CFO, CLO, and CPO to prepare for Phase III data readout and potential commercialization. As of June 30, 2026, the company continues to advance its clinical pipeline while managing its restructured debt and warrant obligations.